Assessing Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch

Simply Wall St.03-17

AdvertisementWhy Natera Stock Is Back in Focus Natera (NTRA) is back on many investors’ radars after two fresh peer-reviewed studies on its Signatera cancer assay and the commercial launch of Zenith ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620426647?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-17 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620426647","market":"hk","top_or_hot":-1,"title":"Assessing Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Natera Stock Is Back in Focus Natera (NTRA) is back on many investors’ radars after two fresh peer-reviewed studies on its Signatera cancer assay and the commercial launch of Zenith ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/assessing-natera-ntra-valuation-after-new-signatera-data-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 18:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/assessing-natera-ntra-valuation-after-new-signatera-data-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Natera Stock Is Back in Focus Natera (NTRA) is back on many investors’ radars after two fresh peer-reviewed studies on its Signatera cancer assay and the commercial launch of Zenith ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/assessing-natera-ntra-valuation-after-new-signatera-data-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0345770308.USD","symbol_name":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/assessing-natera-ntra-valuation-after-new-signatera-data-and","article_id":"2620426647","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/assessing-natera-ntra-valuation-after-new-signatera-data-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620426647","pubTimestamp":1773742865,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Natera Stock Is Back in Focus\nNatera (NTRA) is back on many investors’ radars after two fresh peer-reviewed studies on its Signatera cancer assay and the commercial launch of Zenith genomics for rare disease testing.\nThese developments speak directly to how Natera’s technology is being used in real clinical settings, from monitoring relapse risk in anal and rectal cancers to shortening the diagnostic journey for rare disease patients.\nSee our latest analysis for Natera.\nAt a share price...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","NTRA":"Natera, Inc.","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC"},"translate_title":"在新的Signatera数据和Zenith Genomics发布后评估Natera(NTRA)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1.5},"content_text":"AdvertisementWhy Natera Stock Is Back in Focus Natera (NTRA) is back on many investors’ radars after two fresh peer-reviewed studies on its Signatera cancer assay and the commercial launch of Zenith genomics for rare disease testing. These developments speak directly to how Natera’s technology is being used in real clinical settings, from monitoring relapse risk in anal and rectal cancers to shortening the diagnostic journey for rare disease patients. See our latest analysis for Natera. At a share price of US$197.68, Natera has seen a 5.23% one day share price return after the Signatera and Zenith updates. However, the 90 day share price return of 13.07% and year to date share price return of 13.62% point to fading near term momentum compared with a much stronger 1 year total shareholder return of 32.45% and very large 3 year total shareholder return of around 2.5x. If this kind of genomics news has your attention, it could be a good moment to widen your watchlist with other health focused names using our healthcare AI stocks screener, starting with the 33 healthcare AI stocks. With shares up 32.45% over the past year but showing a 13.62% decline year to date, and trading at an intrinsic discount of about 7%, is Natera now underappreciated, or is the market already accounting for its next leg of growth? Most Popular Narrative: 23.1% Undervalued At a last close of $197.68 against a narrative fair value of about $257.20, the current price sits well below what this widely followed model implies Natera could be worth. This sets the scene for a closer look at what is driving that gap.  Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion.  Read the complete narrative. Want to see what sits behind that expansion story? The narrative is based on expectations of faster top line growth, improving margins, and a rich earnings multiple that all have to line up. Result: Fair Value of $257.20 (UNDERVALUED). Have a read of the narrative in full and understand what's behind the forecasts. However, there is still clear execution risk, especially around clinical trial outcomes and reimbursement decisions, which could quickly challenge the current underpriced narrative. Find out about the key risks to this Natera narrative. Another Lens On Value: Revenue Multiple Sends A Different Signal Our DCF based fair value suggests Natera is about 7% below intrinsic value, yet the current P/S of 12.1x sits above both the estimated fair ratio of 8.7x and the US Biotechs average of 11.3x. That gap points to higher expectations baked into the price. The question is which signal you trust more. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:NTRA P/S Ratio as at Mar 2026Next Steps The mix of optimism and caution in this story is clear, so do not wait for the next headline to form an opinion. Take a closer look at the company’s upside drivers through the 3 key rewards Looking For More Investment Ideas? If you are serious about building a stronger portfolio, use these screeners now so you are not looking back later wishing you had started today.  Target dependable cash generators by scanning for companies with resilient finances using the solid balance sheet and fundamentals stocks screener (42 results). Hunt for potential mispriced opportunities by reviewing the 47 high quality undervalued stocks that combine quality fundamentals with appealing valuations. Prioritise stability and capital protection by focusing on the 74 resilient stocks with low risk scores that score well on downside risk metrics.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620426647","isCrawlerRequest":true}